EUCTR2005-004747-64-IT进行中（未招募）不适用
A Phase 3, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder HIIP Compared to Preprandial Injectable Insulin in Insulin-Na ve Patients with Type 2 Diabetes Mellitus
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ELI LILLY
- 入组人数
- 420
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A Phase 3, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) Compared to Preprandial InjectableInsulin in Insulin-Naïve Patients with Type 2 Diabetes Mellitus - IDAMale or female adults (>18 yrs), diagnosed type 2 diabetes mellitus for at least 6 months duration at study entry, taking at least one oral anti-hyperglycemic medication and are insulin-naïve. They should have a HbA1c =6.5% and =10.0% at the time of screening.EUCTR2005-004747-64-DEEli Lilly and Company Ltd420
进行中（未招募）
不适用
A Phase 3, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) Compared to Preprandial InjectableInsulin in Insulin-Naïve Patients with Type 2 Diabetes Mellitus - IDAMale or female adults (>18 yrs), diagnosed type 2 diabetes mellitus for at least 6 months duration at study entry, taking at least one oral anti-hyperglycemic medication and are insulin-naïve. They should have a HbA1c =6.5% and =10.0% at the time of screening.EUCTR2005-004747-64-HUEli Lilly and Company Ltd420
进行中（未招募）
不适用
A Phase 3, Open-Label, Parallel Group Study to Evaluate the Efficacy of Preprandial Human Insulin Inhalation Powder HIIP Compared to Preprandial Injectable Insulin in Patients with Type 1 Diabetes Mellitus. - NDMedDRA version: 6.1Level: PTClassification code 10012601Type 1 Diabetes MellitusEUCTR2006-000497-80-ITELI LILLY320
进行中（未招募）
不适用
A Phase 3, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) Compared to Preprandial InjectableInsulin in Insulin-Naïve Patients with Type 2 Diabetes Mellitus - IDAMale or female adults (>18 yrs), diagnosed type 2 diabetes mellitus for at least 6 months duration at study entry, taking at least one oral anti-hyperglycemic medication and are insulin-naïve. They should have a HbA1c =6.5% and =10.0% at the time of screening.EUCTR2005-004747-64-PTEli Lilly and Company Ltd420
进行中（未招募）
不适用
A Phase 3, Open-Label, Parallel-Group Study to Evaluate the Efficacy of Preprandial Human Insulin Inhalation Powder (HIIP) Compared to Preprandial InjectableInsulin in Patients with Type 1 Diabetes Mellitus - IDAVMale or female nonsmoking patients 18 years of age or older who have had type 1 diabetes mellitus for at least 24 months at study entry and are taking at least 2 or 3 preprandial injections per day for at least 2 months, have FEV1 and DLCO >70% predicted, and have an HbA1c less or equal 11.0% at screening.EUCTR2006-000497-80-BEEli Lilly and Company Ltd320